Your browser doesn't support javascript.
loading
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Prasad, Rohan M; Srivastava, Shaurya; Wang, Enhua; Liu, Jason Z; Gami, Rakesh; Abdelgadir, Ayat; Sharma, Akhil; Rayamajhi, Sumugdha; Tikaria, Richa.
Afiliação
  • Prasad RM; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Srivastava S; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Wang E; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Liu JZ; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Gami R; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Abdelgadir A; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Sharma A; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Rayamajhi S; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
  • Tikaria R; Department of Internal Medicine, Michigan State University, Sparrow Hospital, Lansing, MI.
Perm J ; 26(1): 123-131, 2021 10 29.
Article em En | MEDLINE | ID: mdl-35609158
ABSTRACT

INTRODUCTION:

Relapsing COVID-19 infections have been reported, but their etiology and severity are still unknown. In addition, there have been no cases in the literature that associate relapsing infection with immunosuppression, either from a disease course or medications. CASE PRESENTATION This case series illustrates two patients who developed a relapsed infection, likely from recent rituximab infusions. In addition, both cases depicted a severe form of infection than the initial one. Laboratory investigations revealed these patients were unable to produce COVID-19 antibodies, even though one of the patients received convalescent plasma.

CONCLUSION:

Clinicians should be aware of the possibility of relapsing COVID-19, especially in immunosuppressed patients. Because rituximab induces B-cell depletion, it can also decrease the effectiveness of the COVID-19 vaccine. Therefore, these patients should receive the vaccine before their scheduled rituximab infusion.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rituximab / COVID-19 / Imunossupressores Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Rituximab / COVID-19 / Imunossupressores Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article